

AD _____

Award Number: W81XWH-06-1-0175

TITLE: Identification of Protein Kinases Required for NF2 Signaling

PRINCIPAL INVESTIGATOR: Jonathan Chernoff, M.D., Ph.D.

CONTRACTING ORGANIZATION: Institute for Cancer Research
Philadelphia, PA 19111-2434

REPORT DATE: December 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-12-2006		2. REPORT TYPE Annual		3. DATES COVERED 1 Dec 2005 – 30 Nov 2006	
4. TITLE AND SUBTITLE Identification of Protein Kinases Required for NF2 Signaling				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0175	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jonathan Chernoff, M.D., Ph.D. Email: Jonathan.Chernoff@fccc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Institute for Cancer Research Philadelphia, PA 19111-2434				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.					
14. ABSTRACT The purpose of this concept award grant is to uncover potential drug targets for treatment of Neurofibromatosis type 2 (NF2). We planned a synthetic lethal screen, using RNAi technology to uncover protein kinases and phosphatases that are specifically required for the survival of NF2-null cells. We obtained and reformatted a murine siRNA library against all known protein kinases and phosphatases. We also obtained NF2flox/flox mouse embryo fibroblasts and used Cre recombinase to convert these to a NF2-/- genotype. We then tested a large number of transfection procedures to determine the most effective and least toxic method for delivery of siRNA into these cells, and optimized this procedure for a high throughput assay. Having carefully established the conditions for the screen, we are carrying out the main, most important experiment: the large scale screen for synthetic lethality.					
15. SUBJECT TERMS RNAi screen; synthetic lethality; kinome; phosphatome; NF2					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	7	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Front Cover 1

Standard Form 298 2

Table of Contents 3

Introduction 4

Body 4

Key Research Accomplishments 6

Reportable Outcomes 6

Conclusions 7

References 7

Appendices 7

INTRODUCTION:

The purpose of this concept award grant is to uncover potential drug targets for treatment of NF2. Specifically, we plan a synthetic lethal screen, using RNAi technology to uncover protein kinases and phosphatases that are specifically required for the survival of NF2-null cells.

BODY: We set ourselves four specific tasks. These were:

Task 1. Obtain and amplify mouse shRNA kinase library:

- a. Prepare plasmid DNA from ~1000 kinase shRNA clones, using Qiagen kits.
- b. Determine titer of adenoviruses by plaque method (Months 1-2).

Task 2. Convert plasmids to retroviruses:

- a. Transfect Phoenix packaging cells with each member of the shRNA kinase library, using 96-well plates. Test efficacy of selected retroviral shRNAs against kinases thought to be germane to NF2 signaling, e.g., Pak1, Pak2, and MLK-3.

Task 3. Convert $Nf2^{flox/flox}$ MEFs to $Nf2^{-/-}$ genotype:



- a. Infect $Nf2^{flox/flox}$ MEFs with a retrovirus expressing Cre recombinase and YFP, sort for YFP positive cells

Task 4. Screen shRNA kinase library for effects on growth and morphology of WT and NF2-null MEFs:

- a. Measure density of growth in the presence or absence of transduced shRNAs.
- b. Retest positives from Task 4a to confirm phenotypic effects.
- c. Test for physical interaction of proteins targeted by shRNA and Merlin.

Progress

Tasks 1 and 2. There are several changes in design that are worth noting. First, we decided to use synthetic siRNA rather than plasmid-based shRNA. We did this because we found that the two main commercial shRNA libraries (the Hannon/Elledge Open Biosystems library and the Bernards NKI library) were difficult to work with due to issues of recombination and poor knock-down of several kinase genes tested. These libraries are rapidly evolving (*e.g.*, use of miRNA leader sequences to enhance knock-down, switch to Lentiviral backbone to increase range of infectability, *etc.*) but we were unwilling to wait for the needed technical improvements. In short, while these libraries, in their current incarnation, are useful in mass screens, they are less useful in well-by-well screens such as ours. We therefore obtained a murine kinome and phosphatome siRNA library from Qiagen. The human version of this library has been used by John Blenis to uncover kinases and phosphatases required for cell survival in HeLa cells (MacKeigan, Murphy & Blenis, NCB 7:591, 2005). For these reasons, we did not need to carry out the planned procedures initially listed as tasks 1 and 2, but instead had a new task: obtaining and reformatting the murine siRNA kinome and phosphatome library for use in our synthetic






lethal assay. Because the Qiagen library contains two duplexes for each gene, we made a version of the library in which these two duplexes are combined. This is similar to the strategy taken by the Blenis lab in their study of the kinome and phosphatome, and allows us to do half as many initial transfections.

Task 3. We obtained NF2^{flox/flox} MEFs from Andi McClatchey (Harvard Medical School). These were left as is or converted to NF2 Δ by infection with Adeno GFP (control) or Adeno Cre-GFP, respectively. Cells were sorted twice for GFP, then tested for genotype and phenotype as follows:

Genomic DNA was extracted from control and Cre-treated cells, and analyzed by PCR (Fig. 1). We data show that we efficiently converted the NF2^{flox/flox} allele to NF2 Δ , as demonstrated by the shift in size of PCR products. To test the effects of this conversion on NF2 expression, we carried out immunoblot analysis using NF2-specific antibodies. These results, shown in Fig. 2, demonstrate that removal of the floxed NF2 exons results in loss of NF2 protein. Finally, we also tested the growth properties of the control (NF2^{flox/flox}) and NF2 Δ cells. Our results show that removal of NF2 profoundly alters cell proliferation, as expected for a tumor suppressor (Fig. 3).

Task 4. Given that we are using siRNAs, we needed to establish a successful transfection regimen to achieve effective mRNA knock-down. We tested the following lipid-based reagents: Lipofectamine 2000, Oligofectamine, RNAiFect, Dharmafect, INTERFERin, Lullaby, HiPerfect, and Generaser. We found that the highest level of knock-down was achieved using Lipofectamine 2000 and HiPerfect, and that, in the latter case, efficiency was improved by incubating cells in the absence of serum during transfection. Using these conditions in cells in 6-well plates, we achieved



KEY RESEARCH ACCOMPLISHMENTS: Bulleted list of key research accomplishments emanating from this research.

1. Obtained and reformatted murine kinome and phosphatome siRNA library.
2. Obtained NF2^{flx/flx} MEFs, converted these to NF2Δ using Cre recombinase, and demonstrated that these cells lose NF2 expression and have increased cell proliferation.
3. Evaluated methods of siRNA transfection and optimized use of reagents.

REPORTABLE OUTCOMES:

There are not as yet any reportable outcomes.

CONCLUSION:

We have demonstrated the feasibility of the synthetic lethal screen, overcoming a number of logistical hurdles. As this project is not complete, we have therefore asked for a 1 year, no-cost extension. After a number of design changes and optimizations, the system is up and running, but the most important experiments lie in the months ahead.

REFERENCES:

None.

APPENDICES:

None.